Consistent with these findings, our bioinformatics analysis results and clinical validation demonstrated that SMYD3 expression levels were upregulated in DLBCL and positively correlated with a poor prognosis in DLBCL. The gene discussed is SMYD3; the disease is diffuse large B-cell lymphoma.